PF-06425090 is a Toxoid Vaccine owned by Pfizer, and is involved in 8 clinical trials, which were completed.

PF-06425090 exhibits therapeutic action by producing T-cell immune responses (both CD4+ and CD8+) and preventive antibodies to attack infectious diseases as they enter the body. T-cell immune responses are considered to be vital in fighting with chronic infection. Gene sequence for selected antigens is inserted in DNA and is delivered into the cells of the body. This stimulates universal antibodies and killer T-cells to recognize and kill the various strains of pathogen.

The revenue for PF-06425090 is expected to reach a total of $4.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the PF-06425090 NPV Report.

PF-06425090 is originated and owned by Pfizer.

PF-06425090 Overview

PF-06425090 vaccine is under development for the prevention of Clostridium difficile infections. The vaccine is administered via intramuscular route as powder for suspension. The vaccine candidate is genetically modified toxins in a non-sporulating strain of C. difficile that lacks the toxin genes tcdA and tcdB.

Pfizer Overview

Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.

The company reported revenues of (US Dollars) US$81,288 million for the fiscal year ended December 2021 (FY2021), an increase of 95.2% over FY2020. In FY2021, the company’s operating margin was 29.1%, compared to an operating margin of 18.8% in FY2020. In FY2021, the company recorded a net margin of 27%, compared to a net margin of 22% in FY2020.

Quick View – PF-06425090

Report Segments
  • Innovator
Drug Name
  • PF-06425090
Administration Pathway
  • Intramuscular
Therapeutic Areas
  • Infectious Disease
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.